oligoDOM® is a proprietary breakthrough technology platform that forms unique self-assembling VLPs, or Virus-Like Particles, exposition multiple copies of full-length antigens. The technology is developped:
- Internally, at Osivax, with two universal vaccine programs against Influenza and Coronaviruses, and other confidential indications.
- In collaboration with top-tier academic teams from Oxford University (Malaria), The German Cancer Research Center (DKFZ Deutsches Krebsforschungszentrum) (HPV for Low- and Middle-Income Countries).
